Canakinumab: Human monoclonal IL 1beta antibody in autoinflammatory diseases
Canakinumab (brand name Ilaris, Novartis) is a fully human monoclonal IgG1 antibody that specifically binds and neutralizes the proinflammatory cytokine interleukin 1 beta (IL 1beta). It was approved in Europe in 2009 for the treatment of Cryopyrin associated periodic syndromes (CAPS), and later expanded to include other autoinflammatory diseases such as familial Mediterranean fever (FMF), tumor necrosis factor receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome (HIDS), active systemic juvenile idiopathic arthritis (sJIA), and adult onset Still's disease.
With Canakinumab, a targeted therapy is available for rare, previously difficult to treat autoinflammation syndromes. These diseases are characterized by genetically determined or idiopathic overactivation of the inflammasome, leading to recurrent fever attacks, skin rashes, joint pain, and organ inflammation. The specific IL 1beta inhibition directly addresses the central pathomechanism.
Mechanism of Action
Interleukin 1 beta is one of the central proinflammatory cytokines and is activated by the NLRP3 inflammasome, a multimeric protein complex in immune cells. In autoinflammatory diseases, there is constitutive activation of the inflammasome (for example, through NLRP3 mutation in CAPS or pyrin mutation in FMF), with continuous IL 1beta production and secretion. IL 1beta binds to its receptor IL 1R1 and triggers an inflammatory cascade with fever, acute phase reaction, and organ involvement.
Canakinumab binds with high affinity directly to IL 1beta and neutralizes it before it can activate its receptor. Unlike the IL 1 receptor antagonist anakinra, canakinumab blocks only IL 1beta and not IL 1alpha, which theoretically leads to more selective activity.
Pharmacokinetically, canakinumab has a very long half-life of approximately 26 days, which allows for monthly to three-monthly subcutaneous injections. Long-term suppression of IL 1beta permits very stable disease control in many autoinflammatory diseases.
Indications
- Cryopyrin associated periodic syndromes (CAPS): familial cold autoinflammatory syndrome (FCAS), Muckle Wells syndrome (MWS), neonatal onset multisystem inflammatory disease (NOMID/CINCA)
- Familial Mediterranean fever (FMF): in case of inadequate response to colchicine
- Tumor necrosis factor receptor associated periodic syndrome (TRAPS)
- Hyperimmunoglobulin D syndrome with mevalonate kinase deficiency (HIDS/MKD)
- Active systemic juvenile idiopathic arthritis (sJIA) from 2 years of age
- Adult onset Still's disease (AOSD)
- Off label: recurrent pericarditis, atherosclerosis prevention (CANTOS study showed benefit, but indication not expanded)
Dosage and Administration
CAPS Adults: 150 mg subcutaneously every 8 weeks (body weight over 40 kg) or 2 mg/kg (15 to 40 kg). If response is inadequate, double the dose.
FMF, TRAPS, HIDS in Adults: 150 mg subcutaneously every 4 weeks, if necessary 300 mg every 4 weeks.
sJIA in Children: 4 mg/kg subcutaneously every 4 weeks, maximum 300 mg per dose.
Administration: Injection into abdomen, thigh, upper arm, or buttocks by patients or relatives after appropriate training. Rotate injection sites to avoid local reactions.
Side Effects
Common: upper respiratory tract infections, local reaction at injection site (redness, swelling, pain), fatigue, headache, nausea, diarrhea, dizziness.
Serious: severe infections including opportunistic infections (tuberculosis reactivation, atypical mycobacteriosis, listeriosis, Pneumocystis jirovecii pneumonia); neutropenia, leukopenia; allergic reactions including anaphylaxis; hepatotoxicity; triggering or worsening of malignancies (theoretical risk with long-term immunosuppression, limited study data).
Important: Patients must be informed about symptoms of unusual infections. In case of fever, cough, shortness of breath, or general malaise, immediate medical attention should be sought.
Drug Interactions
- Other biologics and immunosuppressants: additive infection risk, combination should be critically evaluated
- Live vaccines: contraindicated during therapy
- CYP450 substrates: in active inflammation, CYP enzymes are often suppressed. With canakinumab onset of action, CYP function normalizes, which can lead to lower levels of some drugs (e.g., warfarin, cyclosporine, theophylline)
- TNF antagonists and IL 1 receptor antagonists: should not be given concurrently due to additive infection risk
Special Precautions
Pregnancy and Breastfeeding: Data are limited. With clear indication, therapy should be continued during pregnancy, as uncontrolled autoinflammation may be more dangerous for mother and fetus. Use is possible during breastfeeding.
Before Therapy Initiation: Tuberculosis screening (IGRA test, chest X-ray), hepatitis B/C/HIV serology, immunization status check, baseline blood count and liver transaminases.
Monitoring: Blood count and liver transaminases every 3 months. With signs of infection, immediate diagnostics.
Vaccinations: inactivated vaccines are possible and recommended, live vaccines are contraindicated. Update immunization status before therapy initiation.
You might also be interested in
- Anakinra, IL 1 receptor antagonist with daily subcutaneous administration
- Rilonacept, IL 1 receptor trap (USA)
- Colchicin, standard treatment for FMF
- Tocilizumab, IL 6 receptor antibody
- Adalimumab, TNF alpha antibody
Frequently Asked Questions
What are autoinflammatory diseases?
Autoinflammatory diseases are genetically or idiopathically determined disorders in which the innate immune system (particularly the inflammasome) is permanently activated without an apparent trigger. They differ from autoimmune diseases, in which the adaptive immune system attacks the body's own tissue. Typical symptoms are recurrent fever attacks, skin rashes, joint and organ involvement.
How is canakinumab injected?
Canakinumab is injected subcutaneously into the abdomen, thigh, upper arm, or buttocks. Patients or relatives are trained in self-injection after appropriate instruction. The long half-life allows for monthly to three-monthly intervals, which improves medication adherence.
How quickly does canakinumab work?
First clinical improvements in CAPS are often visible within 1 to 2 days after the first injection. Full effect with reduction or disappearance of attacks develops over several weeks. In CAPS and FMF, many patients experience significantly improved quality of life.
What infection risk exists?
Due to IL 1beta inhibition, immune defense is weakened, especially against tuberculosis and some opportunistic pathogens. Before therapy, tuberculosis screening is mandatory. During therapy, medical attention should be sought promptly for any fever or unusual malaise.
Sources
- EMA, Ilaris (Canakinumab) EPAR
- EULAR Recommendations for autoinflammatory diseases
- Gelbe Liste, Canakinumab active substance profile
- BfArM, Federal Institute for Drugs and Medical Devices
Legal Notice and Disclaimer
The information provided on this page is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendation. It is not a substitute for the advice of a licensed physician or pharmacist. Medicines should only be taken on the prescription of a licensed physician or as dispensed by a pharmacy. All information is based on expert information published at the time of preparation and recognized scientific sources; the current package insert of the manufacturer is always authoritative. Sanoliste assumes no liability for completeness, timeliness, or accuracy of the information presented. In case of medical emergency, call the emergency number 112.